


Novartis Pharmaceuticals Corporation

Novartis Pharmaceuticals Corporation

Novartis Pharmaceuticals Corporation, Novartis Institute for Biomedical Research, Novartis Foundation, Novartis Foundation for Science, Novartis Foundation for the Environment



- Novartis
- Novartis
- Novartis



- NEDA**MS
NEDA-4(5) NfL NEDA-5

1MS NEDA-4²

[illegible][illegible][illegible]

MS¹⁰
escalation therapy¹⁰

escalation therapy¹⁰ 2 Early top-down¹⁰

Rapid escalation Early top-down NEDA 2²⁰

[illegible]

Reference

- 1□□□□□□ □□ □□□□□□□□□□□□□□□□□□□□ p148-149 2017□
- 2□Kavaliunas A, et al. Mull Seier J 23(9): 1233-1240, 2017
- 3□Ghezzi A,et al. Neural Ther 8(2): 461-475,2 019
- 4□European study group on intergeron beta-1b in secondary progressive MS. Lancet 352(9139): 1491-1497,1 998
- 5□Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-Beta-Ia in MS (SPECTRIMS) Study Group. Neurology 56(11): 1496-1504, 2001
- 6□Cohen JA, et al. Neurology 59(5): 679-687, 2002
- 7□The North American Study Group on Interferon beta-1b in Secondary Progressive MS. Neurology 63(10): 1788-1795,2 004

Source URL: <https://www.pro.novartis.com/jp-ja/ns/ms/treatment/tc>